 Paul Norman
Concepts (759)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 61 | 2026 | 118 | 10.780 |
Why?
| | Killer Cells, Natural | 57 | 2026 | 481 | 6.940 |
Why?
| | Haplotypes | 46 | 2026 | 500 | 4.410 |
Why?
| | HLA Antigens | 23 | 2026 | 240 | 4.060 |
Why?
| | Alleles | 51 | 2026 | 896 | 4.020 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 37 | 3.370 |
Why?
| | Histocompatibility Antigens Class I | 17 | 2024 | 202 | 3.300 |
Why?
| | HLA-B Antigens | 21 | 2025 | 58 | 2.910 |
Why?
| | HLA-C Antigens | 19 | 2024 | 37 | 2.880 |
Why?
| | Polymorphism, Genetic | 33 | 2026 | 615 | 2.700 |
Why?
| | Genotype | 39 | 2026 | 1857 | 2.390 |
Why?
| | Receptors, KIR3DL1 | 13 | 2024 | 20 | 2.160 |
Why?
| | Selection, Genetic | 13 | 2026 | 263 | 2.060 |
Why?
| | Immunogenetics | 5 | 2024 | 8 | 1.980 |
Why?
| | Receptors, KIR2DL1 | 12 | 2024 | 22 | 1.970 |
Why?
| | Evolution, Molecular | 18 | 2022 | 494 | 1.700 |
Why?
| | Genetic Variation | 20 | 2026 | 976 | 1.350 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 534 | 1.310 |
Why?
| | Humans | 219 | 2026 | 145763 | 1.260 |
Why?
| | Amyotrophic Lateral Sclerosis | 7 | 2026 | 96 | 1.250 |
Why?
| | HLA-A Antigens | 11 | 2023 | 52 | 1.240 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 7 | 1.190 |
Why?
| | Employment | 4 | 2025 | 184 | 1.160 |
Why?
| | Receptors, Immunologic | 10 | 2021 | 209 | 1.090 |
Why?
| | Socioeconomic Factors | 8 | 2024 | 1327 | 1.070 |
Why?
| | Genetics, Population | 12 | 2026 | 217 | 1.040 |
Why?
| | Gene Flow | 3 | 2026 | 87 | 1.020 |
Why?
| | Health Status Disparities | 6 | 2024 | 321 | 1.020 |
Why?
| | Qualitative Research | 12 | 2026 | 1683 | 1.000 |
Why?
| | Gene Frequency | 20 | 2026 | 489 | 0.980 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 47 | 0.980 |
Why?
| | England | 13 | 2025 | 110 | 0.980 |
Why?
| | Retirement | 2 | 2025 | 35 | 0.950 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 77 | 0.950 |
Why?
| | United Kingdom | 14 | 2025 | 358 | 0.930 |
Why?
| | Poverty Areas | 3 | 2019 | 43 | 0.900 |
Why?
| | Software | 5 | 2026 | 680 | 0.880 |
Why?
| | Genome-Wide Association Study | 5 | 2026 | 1430 | 0.860 |
Why?
| | Emergency Service, Hospital | 12 | 2026 | 2383 | 0.850 |
Why?
| | Sequence Deletion | 1 | 2025 | 191 | 0.840 |
Why?
| | Focus Groups | 5 | 2026 | 572 | 0.840 |
Why?
| | Adaptation, Psychological | 8 | 2026 | 719 | 0.840 |
Why?
| | Medication Errors | 1 | 2024 | 85 | 0.820 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 8 | 0.810 |
Why?
| | Genome, Human | 6 | 2025 | 422 | 0.810 |
Why?
| | Residence Characteristics | 3 | 2021 | 375 | 0.800 |
Why?
| | Genetic Predisposition to Disease | 15 | 2026 | 2399 | 0.770 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 206 | 0.760 |
Why?
| | Ligands | 15 | 2023 | 668 | 0.750 |
Why?
| | Multimorbidity | 1 | 2023 | 65 | 0.740 |
Why?
| | Polymorphism, Single Nucleotide | 15 | 2026 | 2181 | 0.740 |
Why?
| | Complement C4 | 2 | 2025 | 26 | 0.730 |
Why?
| | Herpesviridae | 1 | 2022 | 21 | 0.720 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.720 |
Why?
| | Minority Groups | 5 | 2024 | 285 | 0.700 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2025 | 699 | 0.700 |
Why?
| | Primates | 3 | 2019 | 133 | 0.700 |
Why?
| | Quality of Life | 16 | 2025 | 3210 | 0.690 |
Why?
| | Binge Drinking | 2 | 2021 | 45 | 0.690 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 148 | 0.690 |
Why?
| | Health Promotion | 6 | 2024 | 775 | 0.680 |
Why?
| | Patient Safety | 1 | 2024 | 356 | 0.660 |
Why?
| | Communicable Diseases | 1 | 2023 | 166 | 0.650 |
Why?
| | DNA Copy Number Variations | 6 | 2025 | 188 | 0.650 |
Why?
| | Cross-Sectional Studies | 17 | 2024 | 5922 | 0.650 |
Why?
| | Male | 79 | 2026 | 73003 | 0.640 |
Why?
| | Adult | 60 | 2026 | 40872 | 0.640 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 923 | 0.630 |
Why?
| | Major Histocompatibility Complex | 4 | 2025 | 233 | 0.630 |
Why?
| | Hearing Aids | 1 | 2021 | 98 | 0.620 |
Why?
| | Mortality | 2 | 2014 | 380 | 0.620 |
Why?
| | Female | 85 | 2026 | 79035 | 0.620 |
Why?
| | Seizures | 4 | 2019 | 485 | 0.620 |
Why?
| | Censuses | 3 | 2017 | 33 | 0.610 |
Why?
| | Burns | 4 | 2026 | 374 | 0.600 |
Why?
| | Waiting Lists | 3 | 2026 | 266 | 0.600 |
Why?
| | Aortic Aneurysm, Abdominal | 3 | 2017 | 167 | 0.590 |
Why?
| | Somatoform Disorders | 2 | 2016 | 34 | 0.590 |
Why?
| | Middle Aged | 54 | 2026 | 36302 | 0.580 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2023 | 364 | 0.570 |
Why?
| | Peptides | 4 | 2022 | 998 | 0.560 |
Why?
| | Point Mutation | 3 | 2017 | 241 | 0.550 |
Why?
| | Intensive Care Units | 1 | 2024 | 924 | 0.550 |
Why?
| | Receptors, KIR2DL4 | 3 | 2016 | 4 | 0.540 |
Why?
| | Hearing Loss | 1 | 2021 | 249 | 0.540 |
Why?
| | Heterozygote | 1 | 2019 | 314 | 0.530 |
Why?
| | Pan troglodytes | 9 | 2017 | 62 | 0.530 |
Why?
| | Motor Neuron Disease | 3 | 2025 | 20 | 0.530 |
Why?
| | Blood Vessel Prosthesis Implantation | 2 | 2022 | 228 | 0.520 |
Why?
| | Language | 1 | 2020 | 324 | 0.520 |
Why?
| | Psoriasis | 3 | 2024 | 115 | 0.510 |
Why?
| | Body Image | 4 | 2026 | 96 | 0.510 |
Why?
| | Genotyping Techniques | 4 | 2025 | 71 | 0.500 |
Why?
| | Health Status | 3 | 2025 | 835 | 0.500 |
Why?
| | Leukemia | 1 | 2019 | 246 | 0.500 |
Why?
| | Protein Binding | 10 | 2019 | 2240 | 0.490 |
Why?
| | Rural Health Services | 3 | 2025 | 138 | 0.490 |
Why?
| | Mucins | 1 | 2017 | 75 | 0.490 |
Why?
| | Linkage Disequilibrium | 10 | 2017 | 255 | 0.480 |
Why?
| | Quality Improvement | 4 | 2026 | 1296 | 0.470 |
Why?
| | Young Adult | 25 | 2026 | 14251 | 0.460 |
Why?
| | Blood Vessel Prosthesis | 2 | 2022 | 140 | 0.460 |
Why?
| | Population Dynamics | 2 | 2018 | 142 | 0.460 |
Why?
| | Energy Intake | 4 | 2026 | 512 | 0.450 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 41 | 0.450 |
Why?
| | Self Concept | 4 | 2026 | 254 | 0.450 |
Why?
| | Immunoglobulins | 4 | 2023 | 163 | 0.450 |
Why?
| | Weight Loss | 3 | 2019 | 859 | 0.440 |
Why?
| | Endovascular Procedures | 2 | 2022 | 390 | 0.440 |
Why?
| | Family Relations | 1 | 2015 | 88 | 0.440 |
Why?
| | Exons | 1 | 2016 | 364 | 0.430 |
Why?
| | Population | 1 | 2014 | 30 | 0.420 |
Why?
| | Longitudinal Studies | 11 | 2025 | 2967 | 0.420 |
Why?
| | Aged | 31 | 2026 | 26215 | 0.400 |
Why?
| | Sequence Analysis, DNA | 8 | 2025 | 778 | 0.400 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 421 | 0.400 |
Why?
| | Wales | 5 | 2025 | 26 | 0.400 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.400 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 9 | 0.400 |
Why?
| | Immunity, Innate | 7 | 2024 | 835 | 0.400 |
Why?
| | Terminally Ill | 1 | 2014 | 40 | 0.400 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 24 | 0.400 |
Why?
| | HLA-DRB1 Chains | 4 | 2026 | 110 | 0.400 |
Why?
| | Behavior Therapy | 4 | 2023 | 296 | 0.380 |
Why?
| | Cell Line | 8 | 2019 | 2823 | 0.380 |
Why?
| | Malaria | 1 | 2013 | 72 | 0.370 |
Why?
| | Histocompatibility Testing | 4 | 2024 | 123 | 0.370 |
Why?
| | Overweight | 1 | 2017 | 614 | 0.370 |
Why?
| | T-Lymphocytes | 7 | 2026 | 1997 | 0.360 |
Why?
| | Stents | 2 | 2022 | 564 | 0.360 |
Why?
| | Empathy | 2 | 2024 | 181 | 0.360 |
Why?
| | Adolescent | 24 | 2026 | 22573 | 0.360 |
Why?
| | Attitude of Health Personnel | 4 | 2025 | 1197 | 0.350 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1368 | 0.350 |
Why?
| | Mortality, Premature | 1 | 2011 | 15 | 0.350 |
Why?
| | Noninvasive Ventilation | 2 | 2025 | 62 | 0.350 |
Why?
| | Intention | 3 | 2021 | 186 | 0.340 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2883 | 0.340 |
Why?
| | Infant Mortality | 2 | 2024 | 128 | 0.330 |
Why?
| | Cytomegalovirus | 3 | 2024 | 168 | 0.330 |
Why?
| | Depression | 3 | 2023 | 1557 | 0.330 |
Why?
| | Life Expectancy | 1 | 2011 | 73 | 0.330 |
Why?
| | Thyroid Neoplasms | 2 | 2026 | 370 | 0.330 |
Why?
| | Life Style | 4 | 2017 | 486 | 0.330 |
Why?
| | Universities | 3 | 2021 | 445 | 0.320 |
Why?
| | Australia | 5 | 2024 | 291 | 0.320 |
Why?
| | Phylogeny | 13 | 2026 | 917 | 0.320 |
Why?
| | Behcet Syndrome | 2 | 2021 | 19 | 0.320 |
Why?
| | Emergency Medicine | 2 | 2024 | 282 | 0.310 |
Why?
| | Biological Evolution | 5 | 2019 | 468 | 0.310 |
Why?
| | Alcoholism | 1 | 2017 | 826 | 0.310 |
Why?
| | Health Behavior | 6 | 2025 | 791 | 0.310 |
Why?
| | Epitopes | 8 | 2019 | 473 | 0.310 |
Why?
| | Patient Compliance | 3 | 2025 | 588 | 0.300 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 2131 | 0.300 |
Why?
| | Infant, Newborn | 9 | 2026 | 6464 | 0.300 |
Why?
| | Malnutrition | 2 | 2021 | 86 | 0.290 |
Why?
| | Cause of Death | 1 | 2011 | 471 | 0.290 |
Why?
| | Patient Acceptance of Health Care | 3 | 2026 | 883 | 0.290 |
Why?
| | Recombination, Genetic | 2 | 2010 | 205 | 0.290 |
Why?
| | Models, Molecular | 5 | 2019 | 1599 | 0.290 |
Why?
| | Health Personnel | 4 | 2025 | 757 | 0.290 |
Why?
| | Infant | 10 | 2026 | 10090 | 0.280 |
Why?
| | Cytomegalovirus Infections | 2 | 2024 | 206 | 0.280 |
Why?
| | Meiosis | 1 | 2009 | 101 | 0.280 |
Why?
| | Antigens, CD | 5 | 2017 | 558 | 0.280 |
Why?
| | Newfoundland and Labrador | 5 | 2026 | 5 | 0.280 |
Why?
| | Urban Population | 1 | 2011 | 494 | 0.270 |
Why?
| | Child | 14 | 2026 | 22739 | 0.270 |
Why?
| | Life Change Events | 2 | 2019 | 147 | 0.270 |
Why?
| | Rural Population | 2 | 2018 | 661 | 0.260 |
Why?
| | Alcohol Drinking | 4 | 2021 | 843 | 0.260 |
Why?
| | Chronic Disease | 1 | 2014 | 1812 | 0.260 |
Why?
| | Genomics | 6 | 2025 | 830 | 0.260 |
Why?
| | Students | 3 | 2021 | 652 | 0.260 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2026 | 17 | 0.260 |
Why?
| | Object Attachment | 2 | 2019 | 48 | 0.260 |
Why?
| | China | 3 | 2024 | 273 | 0.260 |
Why?
| | Oceania | 2 | 2024 | 5 | 0.250 |
Why?
| | Income | 2 | 2019 | 203 | 0.250 |
Why?
| | HLA-DQ beta-Chains | 2 | 2026 | 58 | 0.250 |
Why?
| | Homozygote | 2 | 2025 | 199 | 0.250 |
Why?
| | Signal Transduction | 4 | 2019 | 5223 | 0.250 |
Why?
| | Caregivers | 5 | 2026 | 1074 | 0.250 |
Why?
| | Physicians | 2 | 2026 | 956 | 0.250 |
Why?
| | Immune System | 2 | 2019 | 180 | 0.250 |
Why?
| | Multigene Family | 3 | 2018 | 210 | 0.250 |
Why?
| | Papua New Guinea | 1 | 2026 | 10 | 0.240 |
Why?
| | Egypt | 2 | 2023 | 13 | 0.240 |
Why?
| | Obesity | 2 | 2017 | 3118 | 0.240 |
Why?
| | Centromere | 3 | 2025 | 61 | 0.240 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 5 | 0.240 |
Why?
| | Self-Management | 2 | 2019 | 204 | 0.240 |
Why?
| | Phenotype | 8 | 2024 | 3170 | 0.240 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 302 | 0.230 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2026 | 43 | 0.230 |
Why?
| | Animals | 29 | 2025 | 38097 | 0.230 |
Why?
| | Virus Activation | 2 | 2024 | 94 | 0.230 |
Why?
| | Codon | 2 | 2016 | 92 | 0.230 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2025 | 19 | 0.230 |
Why?
| | Thymus Gland | 2 | 2024 | 312 | 0.230 |
Why?
| | Celiac Disease | 2 | 2026 | 311 | 0.230 |
Why?
| | Acceptance and Commitment Therapy | 1 | 2026 | 32 | 0.220 |
Why?
| | Patient Satisfaction | 4 | 2026 | 712 | 0.220 |
Why?
| | Industry | 1 | 2025 | 42 | 0.220 |
Why?
| | Patient Transfer | 2 | 2026 | 211 | 0.220 |
Why?
| | Smoking | 5 | 2019 | 1477 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 153 | 0.220 |
Why?
| | Hominidae | 2 | 2019 | 87 | 0.220 |
Why?
| | Rural Health | 1 | 2025 | 87 | 0.220 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2025 | 38 | 0.220 |
Why?
| | Body Mass Index | 1 | 2013 | 2447 | 0.210 |
Why?
| | Occupations | 1 | 2024 | 51 | 0.210 |
Why?
| | Capacity Building | 1 | 2025 | 62 | 0.210 |
Why?
| | Interpersonal Relations | 2 | 2019 | 398 | 0.210 |
Why?
| | Attitude to Health | 3 | 2019 | 430 | 0.210 |
Why?
| | Antigens, Neoplasm | 1 | 2026 | 271 | 0.210 |
Why?
| | Th17 Cells | 1 | 2025 | 102 | 0.210 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 22 | 0.210 |
Why?
| | Motivation | 2 | 2026 | 602 | 0.210 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 138 | 0.200 |
Why?
| | Surveys and Questionnaires | 9 | 2026 | 6085 | 0.200 |
Why?
| | Nutrition Therapy | 2 | 2025 | 37 | 0.200 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1211 | 0.200 |
Why?
| | Pedigree | 1 | 2025 | 515 | 0.200 |
Why?
| | Child, Preschool | 9 | 2026 | 11868 | 0.200 |
Why?
| | Phenylurea Compounds | 1 | 2024 | 119 | 0.200 |
Why?
| | Arabs | 2 | 2020 | 10 | 0.200 |
Why?
| | Quinolines | 2 | 2024 | 190 | 0.200 |
Why?
| | Alopecia Areata | 1 | 2023 | 13 | 0.200 |
Why?
| | Cohort Studies | 8 | 2021 | 6032 | 0.200 |
Why?
| | Immunity, Cellular | 1 | 2005 | 274 | 0.190 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 88 | 0.190 |
Why?
| | Parkinson Disease | 2 | 2020 | 601 | 0.190 |
Why?
| | Gene Dosage | 3 | 2021 | 145 | 0.190 |
Why?
| | Canada | 4 | 2025 | 432 | 0.190 |
Why?
| | Efficiency, Organizational | 2 | 2025 | 141 | 0.190 |
Why?
| | Iran | 2 | 2020 | 44 | 0.190 |
Why?
| | Cardiovascular Diseases | 3 | 2021 | 2191 | 0.190 |
Why?
| | Unemployment | 1 | 2022 | 43 | 0.190 |
Why?
| | Incidence | 5 | 2020 | 2933 | 0.190 |
Why?
| | Registries | 4 | 2021 | 2410 | 0.190 |
Why?
| | Time Factors | 11 | 2026 | 7133 | 0.190 |
Why?
| | Health Services Research | 1 | 2025 | 391 | 0.180 |
Why?
| | Computational Biology | 2 | 2025 | 669 | 0.180 |
Why?
| | Leukocytes | 1 | 2004 | 296 | 0.180 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 191 | 0.180 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1133 | 0.180 |
Why?
| | Colon | 1 | 2025 | 309 | 0.180 |
Why?
| | Perception | 1 | 2025 | 378 | 0.180 |
Why?
| | Sequence Alignment | 3 | 2021 | 362 | 0.180 |
Why?
| | Africa, Southern | 2 | 2021 | 6 | 0.180 |
Why?
| | Telomere | 4 | 2025 | 287 | 0.180 |
Why?
| | Colitis | 1 | 2025 | 281 | 0.180 |
Why?
| | Social Stigma | 1 | 2024 | 173 | 0.180 |
Why?
| | Transplantation, Homologous | 5 | 2025 | 419 | 0.180 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 30 | 0.180 |
Why?
| | Health | 1 | 2022 | 82 | 0.170 |
Why?
| | Age Factors | 5 | 2018 | 3346 | 0.170 |
Why?
| | Multilevel Analysis | 1 | 2021 | 36 | 0.170 |
Why?
| | Longevity | 1 | 2023 | 178 | 0.170 |
Why?
| | Eczema | 1 | 2022 | 66 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 334 | 0.170 |
Why?
| | New Zealand | 3 | 2018 | 55 | 0.170 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 13 | 0.170 |
Why?
| | Yersinia pestis | 1 | 2021 | 45 | 0.170 |
Why?
| | Malaysia | 1 | 2020 | 15 | 0.170 |
Why?
| | Interviews as Topic | 4 | 2026 | 916 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 145 | 0.170 |
Why?
| | Professional Practice Location | 1 | 2021 | 26 | 0.170 |
Why?
| | Mindfulness | 1 | 2023 | 136 | 0.170 |
Why?
| | HLA-D Antigens | 1 | 2021 | 30 | 0.170 |
Why?
| | Nutritionists | 1 | 2021 | 24 | 0.160 |
Why?
| | Nutritional Support | 1 | 2021 | 39 | 0.160 |
Why?
| | Plague | 1 | 2021 | 60 | 0.160 |
Why?
| | Patient-Centered Care | 1 | 2026 | 547 | 0.160 |
Why?
| | Physical Appearance, Body | 3 | 2024 | 4 | 0.160 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 509 | 0.160 |
Why?
| | Clinical Protocols | 2 | 2019 | 280 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2025 | 381 | 0.160 |
Why?
| | Base Sequence | 4 | 2016 | 2171 | 0.160 |
Why?
| | Hearing Tests | 1 | 2020 | 53 | 0.160 |
Why?
| | Exercise | 5 | 2019 | 2205 | 0.160 |
Why?
| | Mentoring | 1 | 2023 | 166 | 0.150 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.150 |
Why?
| | Pregnancy | 6 | 2020 | 7215 | 0.150 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 3 | 0.150 |
Why?
| | Transportation | 1 | 2019 | 57 | 0.150 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 32 | 0.150 |
Why?
| | Protozoan Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Diet, Diabetic | 1 | 2019 | 33 | 0.150 |
Why?
| | Case-Control Studies | 7 | 2026 | 3634 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2025 | 489 | 0.150 |
Why?
| | Intestinal Mucosa | 1 | 2025 | 675 | 0.150 |
Why?
| | Indians, North American | 2 | 2015 | 598 | 0.150 |
Why?
| | Hearing | 1 | 2020 | 133 | 0.150 |
Why?
| | B-Lymphocytes | 4 | 2017 | 872 | 0.150 |
Why?
| | Diabetic Foot | 1 | 2019 | 25 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 673 | 0.140 |
Why?
| | Bicycling | 1 | 2019 | 117 | 0.140 |
Why?
| | Phylogeography | 1 | 2019 | 50 | 0.140 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 372 | 0.140 |
Why?
| | Prevalence | 5 | 2019 | 2874 | 0.140 |
Why?
| | Diet | 4 | 2019 | 1278 | 0.140 |
Why?
| | Sex Factors | 4 | 2019 | 2110 | 0.140 |
Why?
| | Aggression | 1 | 2020 | 180 | 0.140 |
Why?
| | Parents | 2 | 2024 | 1407 | 0.140 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 54 | 0.140 |
Why?
| | Cluster Analysis | 2 | 2017 | 501 | 0.140 |
Why?
| | Indians, South American | 2 | 2009 | 23 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 992 | 0.140 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 56 | 0.140 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 10 | 0.140 |
Why?
| | Syk Kinase | 1 | 2017 | 19 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 688 | 0.130 |
Why?
| | Middle East | 1 | 2017 | 18 | 0.130 |
Why?
| | Eye Diseases | 1 | 2019 | 97 | 0.130 |
Why?
| | Flow Cytometry | 7 | 2018 | 1165 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2024 | 488 | 0.130 |
Why?
| | Names | 1 | 2017 | 15 | 0.130 |
Why?
| | Risk Factors | 12 | 2025 | 10917 | 0.130 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 209 | 0.130 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 563 | 0.130 |
Why?
| | Binding Sites | 6 | 2015 | 1311 | 0.130 |
Why?
| | Polymerase Chain Reaction | 6 | 2017 | 1043 | 0.130 |
Why?
| | Walking | 2 | 2019 | 545 | 0.130 |
Why?
| | Lymphocyte Subsets | 3 | 2009 | 78 | 0.130 |
Why?
| | Genetic Testing | 4 | 2002 | 483 | 0.130 |
Why?
| | Pan paniscus | 1 | 2017 | 4 | 0.130 |
Why?
| | Contig Mapping | 1 | 2017 | 9 | 0.130 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 28 | 0.130 |
Why?
| | Air Pollution | 1 | 2021 | 315 | 0.130 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 855 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2601 | 0.130 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 27 | 0.130 |
Why?
| | Pongo | 1 | 2017 | 7 | 0.130 |
Why?
| | Osteosarcoma | 1 | 2018 | 89 | 0.130 |
Why?
| | Models, Genetic | 4 | 2015 | 527 | 0.130 |
Why?
| | Aorta, Abdominal | 1 | 2017 | 52 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 280 | 0.120 |
Why?
| | Epilepsy | 2 | 2019 | 390 | 0.120 |
Why?
| | Alcoholic Beverages | 1 | 2017 | 31 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 100 | 0.120 |
Why?
| | Women's Health | 1 | 2019 | 316 | 0.120 |
Why?
| | Antimicrobial Stewardship | 1 | 2019 | 130 | 0.120 |
Why?
| | Virus Diseases | 1 | 2019 | 216 | 0.120 |
Why?
| | Angiotensin II | 1 | 2017 | 102 | 0.120 |
Why?
| | Sarcoma, Ewing | 1 | 2018 | 103 | 0.120 |
Why?
| | Reference Standards | 1 | 2017 | 177 | 0.120 |
Why?
| | Anxiety | 3 | 2023 | 1122 | 0.120 |
Why?
| | Allied Health Personnel | 1 | 2016 | 53 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2024 | 8346 | 0.120 |
Why?
| | Open Reading Frames | 1 | 2017 | 130 | 0.120 |
Why?
| | Logistic Models | 3 | 2021 | 2139 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 578 | 0.120 |
Why?
| | Molecular Typing | 1 | 2016 | 21 | 0.120 |
Why?
| | Placentation | 2 | 2016 | 52 | 0.120 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 172 | 0.120 |
Why?
| | Feeding Behavior | 2 | 2019 | 692 | 0.120 |
Why?
| | Self Care | 2 | 2016 | 392 | 0.120 |
Why?
| | HIV-1 | 1 | 2022 | 908 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 498 | 0.120 |
Why?
| | Gene Expression | 4 | 2018 | 1478 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 938 | 0.110 |
Why?
| | Dissociative Disorders | 1 | 2015 | 30 | 0.110 |
Why?
| | Crohn Disease | 1 | 2019 | 260 | 0.110 |
Why?
| | Donor Selection | 1 | 2016 | 79 | 0.110 |
Why?
| | Sf9 Cells | 1 | 2015 | 11 | 0.110 |
Why?
| | Age Distribution | 2 | 2018 | 404 | 0.110 |
Why?
| | Spodoptera | 1 | 2015 | 40 | 0.110 |
Why?
| | Sex Distribution | 2 | 2018 | 388 | 0.110 |
Why?
| | Chest Pain | 1 | 2016 | 99 | 0.110 |
Why?
| | Baculoviridae | 1 | 2015 | 44 | 0.110 |
Why?
| | Human Migration | 1 | 2015 | 25 | 0.110 |
Why?
| | Curriculum | 1 | 2022 | 1074 | 0.110 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 46 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2018 | 265 | 0.110 |
Why?
| | Research Report | 1 | 2015 | 86 | 0.110 |
Why?
| | Social Class | 1 | 2017 | 264 | 0.110 |
Why?
| | Insecta | 1 | 2015 | 71 | 0.110 |
Why?
| | Adolescent Behavior | 1 | 2020 | 497 | 0.110 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 219 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
| | Polynesia | 1 | 2014 | 3 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
| | Biological Assay | 1 | 2015 | 132 | 0.110 |
Why?
| | Isoantibodies | 1 | 1995 | 57 | 0.110 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 93 | 0.110 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1969 | 0.110 |
Why?
| | DNA | 3 | 2021 | 1437 | 0.100 |
Why?
| | HLA-DQ Antigens | 2 | 2026 | 174 | 0.100 |
Why?
| | Muscle Weakness | 1 | 2014 | 92 | 0.100 |
Why?
| | Risk Reduction Behavior | 1 | 2015 | 217 | 0.100 |
Why?
| | Protein Folding | 1 | 2015 | 277 | 0.100 |
Why?
| | Mammals | 1 | 2015 | 286 | 0.100 |
Why?
| | Glucose | 1 | 2019 | 1048 | 0.100 |
Why?
| | Kidney Transplantation | 2 | 2003 | 712 | 0.100 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 27 | 0.100 |
Why?
| | Prospective Studies | 7 | 2024 | 8075 | 0.100 |
Why?
| | Tissue Donors | 4 | 2024 | 420 | 0.100 |
Why?
| | Counseling | 1 | 2016 | 401 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2011 | 244 | 0.100 |
Why?
| | Species Specificity | 4 | 2017 | 546 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2020 | 981 | 0.100 |
Why?
| | Thinness | 1 | 2013 | 100 | 0.100 |
Why?
| | Cell Differentiation | 4 | 2024 | 2050 | 0.100 |
Why?
| | Seals, Earless | 1 | 2012 | 5 | 0.090 |
Why?
| | Interrupted Time Series Analysis | 2 | 2026 | 75 | 0.090 |
Why?
| | Exome | 1 | 2014 | 229 | 0.090 |
Why?
| | DNA Primers | 4 | 2018 | 505 | 0.090 |
Why?
| | Genetics, Medical | 3 | 2019 | 23 | 0.090 |
Why?
| | Metagenomics | 1 | 2014 | 149 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2025 | 11793 | 0.090 |
Why?
| | Stress, Psychological | 2 | 2016 | 1149 | 0.090 |
Why?
| | Anxiety Disorders | 1 | 2016 | 371 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 435 | 0.090 |
Why?
| | Hepatitis C | 1 | 2015 | 256 | 0.090 |
Why?
| | Graft Survival | 1 | 1995 | 519 | 0.090 |
Why?
| | Saliva | 1 | 2014 | 249 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2019 | 3937 | 0.090 |
Why?
| | Environment | 1 | 2013 | 293 | 0.090 |
Why?
| | CD56 Antigen | 2 | 2009 | 34 | 0.090 |
Why?
| | Scotland | 1 | 2011 | 38 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 286 | 0.090 |
Why?
| | Health Surveys | 1 | 2013 | 520 | 0.090 |
Why?
| | Self Efficacy | 1 | 2015 | 413 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1191 | 0.080 |
Why?
| | Graft Rejection | 1 | 1995 | 521 | 0.080 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2017 | 784 | 0.080 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 9 | 0.080 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 74 | 0.080 |
Why?
| | Internet | 1 | 2015 | 693 | 0.080 |
Why?
| | Immunoglobulin G | 1 | 1995 | 892 | 0.080 |
Why?
| | Triage | 2 | 2026 | 250 | 0.080 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 668 | 0.080 |
Why?
| | North America | 2 | 2021 | 303 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 731 | 0.080 |
Why?
| | Europe | 2 | 2021 | 421 | 0.080 |
Why?
| | Cost-Benefit Analysis | 3 | 2025 | 644 | 0.080 |
Why?
| | Graft vs Host Disease | 2 | 2025 | 279 | 0.080 |
Why?
| | Gene Conversion | 1 | 2009 | 7 | 0.080 |
Why?
| | Family | 1 | 2014 | 685 | 0.080 |
Why?
| | Gene Products, nef | 1 | 2009 | 12 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 474 | 0.080 |
Why?
| | Receptors, IgG | 2 | 2014 | 77 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1399 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2013 | 253 | 0.070 |
Why?
| | Self Report | 1 | 2014 | 876 | 0.070 |
Why?
| | Hospitals | 1 | 2014 | 733 | 0.070 |
Why?
| | Hospitalization | 2 | 2023 | 2460 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1101 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 102 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 126 | 0.070 |
Why?
| | Algorithms | 3 | 2024 | 1850 | 0.070 |
Why?
| | Nutritional Status | 2 | 2021 | 353 | 0.070 |
Why?
| | Africa | 3 | 2019 | 119 | 0.070 |
Why?
| | Insulin | 1 | 2019 | 2516 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2602 | 0.070 |
Why?
| | Homocysteine | 1 | 2008 | 152 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1925 | 0.070 |
Why?
| | Regression Analysis | 2 | 2021 | 1001 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1491 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 376 | 0.070 |
Why?
| | Breast Neoplasms | 4 | 2002 | 2393 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2667 | 0.060 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2004 | 26 | 0.060 |
Why?
| | Namibia | 1 | 2026 | 1 | 0.060 |
Why?
| | Botswana | 1 | 2026 | 11 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 387 | 0.060 |
Why?
| | Receptors, Fc | 1 | 2007 | 54 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1420 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2025 | 947 | 0.060 |
Why?
| | HIV Infections | 1 | 2022 | 3195 | 0.060 |
Why?
| | Genetic Counseling | 3 | 2002 | 80 | 0.060 |
Why?
| | Neoplasms | 2 | 2017 | 2913 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4568 | 0.060 |
Why?
| | Risk | 3 | 2019 | 923 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2026 | 29 | 0.060 |
Why?
| | Brazil | 1 | 2026 | 179 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2007 | 214 | 0.060 |
Why?
| | HLA-DR Antigens | 2 | 2006 | 220 | 0.060 |
Why?
| | Trinidad and Tobago | 2 | 2002 | 5 | 0.060 |
Why?
| | Genetic Loci | 2 | 2019 | 267 | 0.060 |
Why?
| | Norway | 1 | 2025 | 41 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 374 | 0.060 |
Why?
| | Ireland | 1 | 2025 | 32 | 0.060 |
Why?
| | Equivalence Trials as Topic | 1 | 2025 | 35 | 0.060 |
Why?
| | Mice | 5 | 2025 | 18355 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2933 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2019 | 115 | 0.060 |
Why?
| | INDEL Mutation | 1 | 2025 | 22 | 0.060 |
Why?
| | Kinetochores | 1 | 2025 | 52 | 0.060 |
Why?
| | Palliative Care | 1 | 2014 | 1022 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2017 | 4151 | 0.050 |
Why?
| | Stroke | 1 | 2014 | 1271 | 0.050 |
Why?
| | Recurrence | 2 | 2021 | 1139 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2025 | 3130 | 0.050 |
Why?
| | Models, Statistical | 2 | 2019 | 672 | 0.050 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3551 | 0.050 |
Why?
| | Histocompatibility | 1 | 2003 | 20 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 178 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 632 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5992 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2024 | 132 | 0.050 |
Why?
| | Prognosis | 2 | 2025 | 4329 | 0.050 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 413 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 157 | 0.050 |
Why?
| | Granzymes | 1 | 2023 | 49 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 442 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 453 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 327 | 0.050 |
Why?
| | Lymphocytes | 1 | 2005 | 376 | 0.050 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 122 | 0.050 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 27 | 0.050 |
Why?
| | Africa, Western | 1 | 2002 | 21 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2002 | 44 | 0.040 |
Why?
| | Pakistan | 1 | 2002 | 79 | 0.040 |
Why?
| | Bangladesh | 1 | 2002 | 63 | 0.040 |
Why?
| | Pandemics | 2 | 2021 | 1711 | 0.040 |
Why?
| | Cloning, Molecular | 2 | 2014 | 538 | 0.040 |
Why?
| | Risk Assessment | 4 | 2019 | 3752 | 0.040 |
Why?
| | Software Design | 1 | 2021 | 25 | 0.040 |
Why?
| | India | 1 | 2002 | 213 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 38 | 0.040 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 114 | 0.040 |
Why?
| | Cytokines | 2 | 2025 | 2069 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 65 | 0.040 |
Why?
| | Thailand | 1 | 2001 | 19 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 361 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2021 | 90 | 0.040 |
Why?
| | Odds Ratio | 2 | 2017 | 1083 | 0.040 |
Why?
| | Twins | 1 | 2001 | 152 | 0.040 |
Why?
| | Geography | 1 | 2021 | 187 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 968 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 693 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2021 | 330 | 0.040 |
Why?
| | Cholesterol, HDL | 1 | 2021 | 201 | 0.040 |
Why?
| | Length of Stay | 1 | 2026 | 1350 | 0.040 |
Why?
| | Leadership | 1 | 2024 | 402 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 356 | 0.040 |
Why?
| | Breathing Exercises | 1 | 2019 | 21 | 0.040 |
Why?
| | Genetic Markers | 1 | 2001 | 338 | 0.040 |
Why?
| | Respiratory Muscles | 1 | 2019 | 37 | 0.040 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2019 | 29 | 0.040 |
Why?
| | Electric Impedance | 1 | 2019 | 108 | 0.040 |
Why?
| | Deglutition | 1 | 2019 | 73 | 0.040 |
Why?
| | Patient Acuity | 1 | 2019 | 48 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 291 | 0.040 |
Why?
| | Communication | 1 | 2026 | 977 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 741 | 0.040 |
Why?
| | Hospital Units | 1 | 2019 | 32 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 39 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2019 | 49 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 32 | 0.040 |
Why?
| | Group Processes | 1 | 2019 | 63 | 0.040 |
Why?
| | Ketones | 1 | 2019 | 50 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2019 | 89 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2019 | 67 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1139 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 4090 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 66 | 0.040 |
Why?
| | Western Australia | 1 | 2018 | 8 | 0.040 |
Why?
| | Triglycerides | 1 | 2021 | 520 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 92 | 0.040 |
Why?
| | Chromosome Mapping | 2 | 2014 | 507 | 0.030 |
Why?
| | Cough | 1 | 2019 | 124 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2865 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2021 | 347 | 0.030 |
Why?
| | Posture | 1 | 2019 | 197 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 420 | 0.030 |
Why?
| | Ankle Brachial Index | 1 | 2018 | 41 | 0.030 |
Why?
| | Parenting | 1 | 2022 | 319 | 0.030 |
Why?
| | Biomarkers | 2 | 2021 | 4302 | 0.030 |
Why?
| | Particulate Matter | 1 | 2021 | 326 | 0.030 |
Why?
| | Body Height | 1 | 2019 | 203 | 0.030 |
Why?
| | Narration | 1 | 2019 | 80 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 981 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 195 | 0.030 |
Why?
| | Deglutition Disorders | 1 | 2019 | 154 | 0.030 |
Why?
| | Demography | 2 | 2013 | 282 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 536 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2017 | 12 | 0.030 |
Why?
| | Collagen Type III | 1 | 2017 | 15 | 0.030 |
Why?
| | Butyrophilins | 1 | 2017 | 5 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1180 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 7 | 0.030 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 21 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2017 | 53 | 0.030 |
Why?
| | Gorilla gorilla | 1 | 2017 | 17 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 183 | 0.030 |
Why?
| | Lymphocyte Count | 3 | 2002 | 165 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 635 | 0.030 |
Why?
| | Elastin | 1 | 2017 | 78 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 399 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2017 | 93 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 1003 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2017 | 131 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 133 | 0.030 |
Why?
| | Proteolysis | 1 | 2017 | 172 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5428 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 125 | 0.030 |
Why?
| | Cross Infection | 1 | 2019 | 260 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 177 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 890 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 410 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1899 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1509 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1505 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 326 | 0.030 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 101 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 18 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 251 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 79 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 7 | 0.030 |
Why?
| | Nursing Staff | 1 | 2016 | 41 | 0.030 |
Why?
| | Americas | 1 | 2015 | 27 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 92 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 740 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 167 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 53 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 48 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 446 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 618 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 224 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 238 | 0.030 |
Why?
| | Attitude | 1 | 2017 | 259 | 0.030 |
Why?
| | Vascular Remodeling | 1 | 2017 | 209 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 1146 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 944 | 0.030 |
Why?
| | Fruit | 1 | 2015 | 146 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 28 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 322 | 0.030 |
Why?
| | Smoking Prevention | 1 | 2015 | 166 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 437 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 364 | 0.030 |
Why?
| | Vegetables | 1 | 2015 | 162 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 57 | 0.030 |
Why?
| | Social Support | 1 | 2019 | 651 | 0.030 |
Why?
| | Patient Care Team | 1 | 2000 | 697 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 553 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 266 | 0.030 |
Why?
| | Hypoglycemia | 1 | 2019 | 480 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 259 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 298 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 777 | 0.030 |
Why?
| | Models, Psychological | 1 | 2015 | 294 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 29 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 307 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 86 | 0.020 |
Why?
| | Hepacivirus | 1 | 2015 | 242 | 0.020 |
Why?
| | Inflammation | 1 | 2025 | 2883 | 0.020 |
Why?
| | Reproduction | 1 | 2015 | 208 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2015 | 371 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2015 | 268 | 0.020 |
Why?
| | Transplant Recipients | 1 | 2015 | 182 | 0.020 |
Why?
| | United States | 2 | 2023 | 16123 | 0.020 |
Why?
| | Asia | 2 | 2003 | 70 | 0.020 |
Why?
| | Cultural Competency | 1 | 2014 | 89 | 0.020 |
Why?
| | Lung | 2 | 2019 | 4116 | 0.020 |
Why?
| | Ultrasonography | 1 | 2017 | 788 | 0.020 |
Why?
| | Ursidae | 1 | 2012 | 8 | 0.020 |
Why?
| | Smad Proteins | 1 | 2012 | 42 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 709 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1036 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 55 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 361 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 211 | 0.020 |
Why?
| | Genome | 1 | 2014 | 305 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 946 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 1975 | 337 | 0.020 |
Why?
| | Feces | 1 | 2015 | 496 | 0.020 |
Why?
| | Family Practice | 1 | 1975 | 407 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 381 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2015 | 441 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1992 | 108 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3416 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 48 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2016 | 1115 | 0.020 |
Why?
| | Models, Biological | 2 | 2016 | 1764 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2013 | 368 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 478 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 36 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1101 | 0.020 |
Why?
| | Twins, Dizygotic | 2 | 2001 | 108 | 0.020 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2012 | 138 | 0.020 |
Why?
| | Twins, Monozygotic | 2 | 2001 | 133 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 308 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 228 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 383 | 0.020 |
Why?
| | Culture | 1 | 2011 | 124 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 2000 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2514 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 60 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 116 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 387 | 0.020 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 36 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 371 | 0.020 |
Why?
| | Pyridoxine | 1 | 2008 | 37 | 0.020 |
Why?
| | Personality Inventory | 1 | 2008 | 134 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 263 | 0.020 |
Why?
| | Aging | 1 | 2019 | 1973 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 182 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 486 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2008 | 135 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 696 | 0.020 |
Why?
| | Hemodynamics | 1 | 2012 | 1118 | 0.020 |
Why?
| | Folic Acid | 1 | 2008 | 198 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 910 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 305 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 7 | 0.020 |
Why?
| | Microbiota | 1 | 2014 | 730 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2007 | 147 | 0.010 |
Why?
| | Rabbits | 1 | 2007 | 653 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 23 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2005 | 70 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 787 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 87 | 0.010 |
Why?
| | Microspheres | 1 | 2005 | 142 | 0.010 |
Why?
| | Cell Separation | 1 | 2005 | 306 | 0.010 |
Why?
| | Genetic Techniques | 1 | 2004 | 66 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2005 | 322 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1247 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 48 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1166 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 351 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 256 | 0.010 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 22 | 0.010 |
Why?
| | Utah | 1 | 2002 | 80 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1751 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 282 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 528 | 0.010 |
Why?
| | Genes, BRCA1 | 1 | 2000 | 45 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2000 | 164 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 17325 | 0.010 |
Why?
| | BRCA2 Protein | 1 | 2000 | 68 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 838 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1547 | 0.010 |
Why?
| | Ambulatory Care Facilities | 1 | 2000 | 269 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2000 | 1300 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2000 | 469 | 0.010 |
Why?
| | Hospital Departments | 1 | 1975 | 9 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2000 | 868 | 0.010 |
Why?
| | Receptors, Leukotriene B4 | 1 | 1992 | 7 | 0.010 |
Why?
| | SRS-A | 1 | 1992 | 17 | 0.010 |
Why?
| | Receptors, Leukotriene | 1 | 1992 | 13 | 0.010 |
Why?
| | Dicarboxylic Acids | 1 | 1992 | 12 | 0.010 |
Why?
| | Leukotriene E4 | 1 | 1992 | 24 | 0.010 |
Why?
| | Propionates | 1 | 1992 | 39 | 0.010 |
Why?
| | Transcription Factors | 1 | 2000 | 1736 | 0.010 |
Why?
| | Cysteine | 1 | 1992 | 211 | 0.010 |
Why?
| | Muscle Contraction | 1 | 1992 | 429 | 0.000 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|